Zacks Bull and Bear of the Day Highlights: Winnebago Industries, Gold Fields, Teva Pharmaceutical Industries, Biogen and

Zacks Bull and Bear of the Day Highlights: Winnebago Industries, Gold Fields,
             Teva Pharmaceutical Industries, Biogen and Novartis

PR Newswire

CHICAGO, March 11, 2013

CHICAGO, March 11, 2013 /PRNewswire/ -- Zacks Equity Research highlights
Winnebago Industries, Inc. (NYSE:WGO) as the Bull of the Day and Gold Fields
Limited (NYSE:GFI) as the Bear of the Day. In addition, Zacks Equity Research
provides analysis on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Biogen
(Nasdaq:BIIB) and Novartis (NYSE:NVS).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Full analysis of all these stocks is available at
http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

How can you tell the economy is back? Because consumers are buying RVs again.
Winnebago Industries, Inc. (NYSE:WGO) managed to make it through the Great
Recession, gobbling up market share along the way. This Zacks Rank #1 (Strong
Buy) is now poised for triple digit earnings growth in 2013 as RV sales
rebound.

Winnebago's brand recognition is so strong that when you think of RVs it's the
first name that comes to mind. Founded in 1958 in Iowa, Winnebago manufactures
a variety of recreation vehicles ("RVs") including motor homes, travel
trailers and fifth wheel products.

Given consolidation in the industry during the Great Recession, Winnebago was
able to add to its market share and now has about 20% of the RV market.

Motor home sales peaked in 2004 at 69,000 and plunged during the Great
Recession. By 2011, only 25,000 motor homes were shipped. But that number is
expected to slowly rise as the economy improves and the Baby Boomers age.

Bear of the Day:

It's tough being a gold miner in 2013. Gold prices have slid to 8 month lows.
Many miners are also having trouble getting the yellow metal out of the
ground. Gold Fields Limited (NYSE:GFI) , a South African miner, recently
provided disappointing 2013 production guidance which sent earnings estimates
tumbling. It's a Zacks Rank #5 (Strong Sell).

Gold Fields is an unhedged gold producer with 6 operating mines in Australia,
Ghana, Peru and South Africa. Four other projects are ongoing.

Even if gold prices are elevated, a gold miner doesn't make money without
getting it out of the ground. A whole host of things can impact production
from natural disasters to geopolitical risks to power outages due to poor
infrastructure.

In the fourth quarter of 2012, Gold Fields suffered from major strikes. Gold
production fell 7% in the quarter due to the strikes.

Latest Posts on the Zacks Analyst Blog:

Teva Enrolls Patients in MS Study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech recently
announced that the first patient for their phase III CONCERTO study has been
enrolled.

The multinational, randomized, double-blind placebo-controlled study is being
conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two
doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study with
the primary endpoint being confirmed disability progression as measured by the
Expanded Disability Status Scale (EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and
BRAVO) earlier. The candidate is also being studied for Crohn's disease and
lupus.

The successful development and launch of laquinimod would help strengthen
Teva's multiple sclerosis drug portfolio. Being an oral formulation,
laquinimod could provide an advantage over therapies that require injection or
infusion.

Teva already has a multiple sclerosis product in its portfolio – Copaxone.
Copaxone is approved for the reduction of the frequency of relapses in RRMS,
including patients who have experienced a first clinical episode and have MRI
features consistent with multiple sclerosis.

We are pleased with Teva's efforts to expand its multiple sclerosis franchise.
The multiple sclerosis market represents significant commercial potential. The
disease is estimated to affect more than 400,000 people in the US . Worldwide,
it is estimated that more than two million people may be suffering from
multiple sclerosis.

Key players in the multiple sclerosis market include Biogen (Nasdaq:BIIB) and
Novartis (NYSE:NVS) among others.

Get the full analysis of all these stocks by going to
http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting http://at.zacks.com/?id=7158.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com